CD8A and neoplasm: Although we did not observe a dose-dependent increase of OVA-specific CD8+ T cells in the spleen, lung and liver, analysis of tumor tissue revealed a dose-dependent increase of CTLs starting 10 days after vaccination, potentially explaining the therapeutic benefit of including higher αGC-doses.